BioSpace News Archive

Drug Development

Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi’s Libtayo® in CSCC

October 15, 2019
·
10 min read
Business

Trio Health Names Ramita Tandon Chief Operating Officer

Hire Comes Just Weeks After Major Announcement with Greenleaf Health

October 15, 2019
·
3 min read
Business

Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, announced the appointment of Thomas Schlumpberger, Ph.D., as Executive Vice President, Diagnostics.

October 15, 2019
·
4 min read
Biotech Beach

New Data from Ambry Genetics Demonstrates Impact of First Major Advancement in Over 10 Years to Increase Diagnostic Yield in Genetic Testing for Hereditary Cancer Risk

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results.

October 15, 2019
·
6 min read
Business

Checkmate Pharmaceuticals Announces Additions to Management Team

Experienced Industry Executives to Lead Clinical Research and Regulatory Affairs with the Appointments of James Wooldridge, MD, as Chief Medical Officer and Steven Hamburger, PhD, as Vice President of Regulatory Affairs

October 15, 2019
·
3 min read
Business

World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board

The company expands its Scientific Advisory Board with four additional RNA splicing, genetics, and disease experts, who join SAB Chair Professor Tyler Jacks & special advisor Professor Phil Sharp as well as several other internationally-recognized SAB members.

October 15, 2019
·
5 min read
Genetown

Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an additional $40.2 million in the company’s Series B financing, for a total of $75.2 million in this financing

October 15, 2019
·
4 min read
Business

BioSig Opens a Technology Development Office in Rochester, MNThe Company joins leading medtech peers in Destination Medical Center’s Discovery Square

BioSig Technologies, Inc. announced that the Company is opening a new technology development office at Discovery Square, a 16 block sub-district built in collaboration with Mayo Clinic in Rochester, Minnesota.

October 15, 2019
·
4 min read
Job Trends

HTG Announces the Launch of its New Autoimmune Profiling Assay

HTG Molecular Diagnostics, Inc. announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory at the end of October 2019.

October 15, 2019
·
4 min read
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

Immutep Limited announces mature positive efficacy data from its TACTI-mel Phase I clinical study combining its lead product candidate, eftilagimod alpha with KEYTRUDA® in metastatic melanoma.

October 15, 2019
·
4 min read